FDA Expands Use of HCV Drug Daclatasvir (Daklinza)

Updated label permits use of the drug for patients with HCV genotype 1 and 3 and HIV-1 coinfection, advanced cirrhosis, and HCV recurrence after liver transplant, the company says.